Javascript must be enabled to continue!
Data from A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance
View through CrossRef
<div>Abstract<p>Adequate energy intake and homeostasis are fundamental for the appropriate growth and maintenance of an organism; the presence of a tumor can break this equilibrium. Tumor energy requests can lead to extreme weight loss in animals and cachexia in cancer patients. Angiogenesis inhibitors, acting on tumor vascularization, counteract this tumor–host energy imbalance, with significant results in preclinical models and more limited results in the clinic. Current pharmacokinetic–pharmacodynamic models mainly focus on the antiangiogenic effects on tumor growth but do not provide information about host conditions. A model that can predict energetic conditions that provide significant tumor growth inhibition with acceptable host body weight reduction is therefore needed. We developed a new tumor-in-host dynamic energy budget (DEB)–based model to account for the cytostatic activity of antiangiogenic treatments. Drug effect was implemented as an inhibition of the energy fraction subtracted from the host by the tumor. The model was tested on seven xenograft experiments involving bevacizumab and three different tumor cell lines. The model successfully predicted tumor and host body growth data, providing a quantitative measurement of drug potency and tumor-related cachexia. The inclusion of a hypoxia-triggered resistance mechanism enabled investigation of the decreased efficacy frequently observed with prolonged bevacizumab treatments. In conclusion, the tumor-in-host DEB-based approach has been extended to account for the effect of bevacizumab. The resistance model predicts the response to different administration protocols and, for the first time, the impact of tumor-related cachexia in different cell lines. Finally, the physiologic base of the model strongly suggests its use in translational human research.</p>Significance:<p>A mathematical model describes tumor growth in animal models, taking into consideration the energy balance involving both the growth of tumor and the physiologic functions of the host.</p></div>
American Association for Cancer Research (AACR)
Title: Data from A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance
Description:
<div>Abstract<p>Adequate energy intake and homeostasis are fundamental for the appropriate growth and maintenance of an organism; the presence of a tumor can break this equilibrium.
Tumor energy requests can lead to extreme weight loss in animals and cachexia in cancer patients.
Angiogenesis inhibitors, acting on tumor vascularization, counteract this tumor–host energy imbalance, with significant results in preclinical models and more limited results in the clinic.
Current pharmacokinetic–pharmacodynamic models mainly focus on the antiangiogenic effects on tumor growth but do not provide information about host conditions.
A model that can predict energetic conditions that provide significant tumor growth inhibition with acceptable host body weight reduction is therefore needed.
We developed a new tumor-in-host dynamic energy budget (DEB)–based model to account for the cytostatic activity of antiangiogenic treatments.
Drug effect was implemented as an inhibition of the energy fraction subtracted from the host by the tumor.
The model was tested on seven xenograft experiments involving bevacizumab and three different tumor cell lines.
The model successfully predicted tumor and host body growth data, providing a quantitative measurement of drug potency and tumor-related cachexia.
The inclusion of a hypoxia-triggered resistance mechanism enabled investigation of the decreased efficacy frequently observed with prolonged bevacizumab treatments.
In conclusion, the tumor-in-host DEB-based approach has been extended to account for the effect of bevacizumab.
The resistance model predicts the response to different administration protocols and, for the first time, the impact of tumor-related cachexia in different cell lines.
Finally, the physiologic base of the model strongly suggests its use in translational human research.
</p>Significance:<p>A mathematical model describes tumor growth in animal models, taking into consideration the energy balance involving both the growth of tumor and the physiologic functions of the host.
</p></div>.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract
Bevacizumab-containing protocols are all based upon the concomitant administration of the drugs given in a row. Bevacizumab is expected to induce a transien...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Association Between Cancer Cachexia and Prognosis in Patients with Head and Neck Squamous Cell Carcinoma Who Received Chemoradiotherapy
Association Between Cancer Cachexia and Prognosis in Patients with Head and Neck Squamous Cell Carcinoma Who Received Chemoradiotherapy
Abstract
Objectives: This retrospective observational study is conducted to evaluate the association between cancer cachexia and prognosis in head and neck cancer patients ...
Abstract 363: Modelling cancer cachexia using a comprehensive panel of heterogeneous esophageal squamous cell carcinoma xenografts for therapeutic application
Abstract 363: Modelling cancer cachexia using a comprehensive panel of heterogeneous esophageal squamous cell carcinoma xenografts for therapeutic application
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is one of deadliest esophageal malignancies in Asia. Cancer cachexia is a multifactorial body wasting ...
Effect of preoperative cancer cachexia on postoperative sarcopenia in patients with non-small cell lung cancer
Effect of preoperative cancer cachexia on postoperative sarcopenia in patients with non-small cell lung cancer
Abstract
Purpose
Many patients with lung cancer have cancer cachexia, which may result in complications and affect prognosis; however, its preoperative prevalence is unkno...
Abstract A017: Optimization of a cachexia animal model for efficacy evaluation of candidates
Abstract A017: Optimization of a cachexia animal model for efficacy evaluation of candidates
Abstract
Cachexia-anorexia syndrome, which is called cancer cachexia, is a common and important indicator of cancer and occurs in 30% to 80% of cancer patients. Canc...
Abstract 1886: Metabolic alterations associated with pancreatic cancer-induced cachexia.
Abstract 1886: Metabolic alterations associated with pancreatic cancer-induced cachexia.
Abstract
Cachexia, a metabolic syndrome, leads to loss of muscle weight and fat tissues. Cancer-induced cachexia accounts for nearly 20% of all cancer-related deaths...

